MYSZ 最新10-Q变化
将 MYSZ 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +19 | −11 | ~6 | 30 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 风险因素 | 部分风险因素更新 | +4 | 0 | ~1 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Six and Three Months Ended June 30, 2026 Compared to Six and Three Months Ended June 30, 2025
Our revenues for the three months ended June 30, 2026 amounted to $3,070,000 compared to $2,006,000 for the three months ended June 30, 2025. The increase in the three months ended June 30, 2025 from the corresponding period is primarily attributable to Amazon sales as well as inclusion of revenue g…
Our cost of revenues expenses for the six months ended June 30, 2026 amounted to $3,551,000 compared to $1,941,000 for the six months ended June 30, 2025. The increase in comparison with the corresponding period was mainly due to increase in amounts sold in Orgad and Rotrade as well as the inclusion…
Our research and development expenses for the six months ended June 30, 2026 amounted to $614,000 compared to $224,000 for the six months ended June 30, 2025. The increase from the corresponding period was mainly due to an increase in salaries expenses due to increased headcount and an increase in s…
Our research and development expenses for the three months ended June 30, 2026 amounted to $375,000 compared to $142,000 for the three months ended June 30, 2025. The increase reflects continued investment in product development, AI capabilities and a larger engineering team supporting the expanded …
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025
Our cost of revenues expenses for the three months ended March 31, 2026 amounted to $1,454,000 compared to $1,059,000 for the three months ended March 31, 2025. The increase in comparison with the corresponding period was mainly due to increase in amounts sold in Orgad and Rotrade.
Our research and development expenses for the three months ended March 31, 2026 amounted to $239,000 compared to $82,000 for the three months ended March 31, 2025. The increase from the corresponding period was mainly due to an increase in salaries expenses due to increased headcount and an increase…
Our general and administrative expenses for the three months ended March 31, 2026 amounted to $1,217,000 compared to $831,000 for the three months ended March 31, 2025. The increase was attributable to the increased in consulting expenses for investor relations as well as the as the inclusion of Per…
As a result of the foregoing, for the three months ended March 31, 2026, our operating loss was $1,406,000 an increase of $320,000, or 33%, compared to our operating loss for the three months ended March 31, 2025 of $1,060,000.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Nasdaq has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive trading d…
We have in the past fallen out of compliance with certain continued listing standards, including the minimum bid price requirement, although we have subsequently been able to regain compliance. No assurance, however, can be given that we will continue to be in compliance with the continued listing r…
On July 22, 2026, the SEC approved a new Nasdaq continued listing requirement applicable to companies listed on the Nasdaq Stock Market that would require listed companies to maintain a minimum MVLS of at least $5.0 million. Under the approved rule, if a company’s MVLS remains below $5.0 million for…
However, on July 29, 2026, the SEC notified Nasdaq that it had received notices of intention to petition for review of the approval order and, pursuant to Rule 431(e) of the SEC’s Rules of Practice, the effectiveness of the approval order was automatically stayed pending further review by the SEC. A…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议